The FDA approved Moderna's mFLUSIVA, the first mRNA-based flu vaccine, for adults aged 50 and older. A Phase 3 trial of nearly 41,000 participants showed the vaccine is 26.6% more effective than standard-dose flu shots in preventing infection.

Plain English

Think of this as the COVID vaccine tech repurposed for the flu. It's faster to produce—taking just two to three months from strain selection to rollout, half the time of traditional egg-based vaccines. The...